Zura Bio Limited (ZURA)
| Bid | 1.16 |
| Market Cap | 73.94M |
| Revenue (ttm) | 2K |
| Net Income (ttm) | -64.44M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -1.55 |
| Forward PE | -1.57 |
| Analyst | Buy |
| Ask | 1.24 |
| Volume | 339,088 |
| Avg. Volume (20D) | 463,339 |
| Open | 1.18 |
| Previous Close | 1.20 |
| Day's Range | 1.08 - 1.21 |
| 52-Week Range | 0.97 - 5.07 |
| Beta | -0.13 |
About ZURA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ZURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
5 days ago · https://www.defenseworld.net
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA)Squarepoint Ops LLC lessened its stake in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 48.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange C...
2 weeks ago · businesswire.com
Zura Bio to Present at the Jefferies Global Healthcare ConferenceHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway anti...
3 weeks ago · businesswire.com
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.
2 months ago · businesswire.com
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway anti...